May 12th, 2022 (Earnings Report)Dear Reader,HealthTechMovers.com just identified several healthtech stocks that are expected to release earnings this week.If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments.Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements.
Athira Pharma
Symbol: ATHA
Recent Price: $$8.42
Average Analyst Price Target: $39.00 (363.18%)
Market Cap: $$316.79M
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Thomas Shrader, analyst at BTIG, reiterates coverage on Athira Pharma (ATHA) in the Healthcare sector with a Buy rating and a price target of $ 33 (2 days ago).
TipRanks.com also reports that Athira Pharma currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $39.00 . The target pricing ranges from a high forecast of $51.00 down to a low forecast of $33.00. Athira Pharma (ATHA)’s last closing price was $$8.42 which would put the average price target at 363.18% upside.Here are 3rd party ratings for ATHA:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 40% (151 out of 253)
--------------------------------------------------------------------------
CTI BioPharma
Symbol: CTIC
Recent Price: $$3.55
Average Analyst Price Target: $8.44 (137.75%)
Market Cap: $$358.62M
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Benjamin Burnett, analyst at Stifel Nicolaus, reiterates coverage on CTI BioPharma (CTIC) in the Healthcare sector with a Buy rating and a price target of $ 6.2 (1 week ago).
TipRanks.com also reports that CTI BioPharma currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.44 . The target pricing ranges from a high forecast of $12.00 down to a low forecast of $6.00. CTI BioPharma (CTIC)’s last closing price was $$3.55 which would put the average price target at 137.75% upside.Here are 3rd party ratings for CTIC:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Bottom 40% (151 out of 253)
--------------------------------------------------------------------------
Knight Therapeutics
Symbol: KHTRF
Recent Price: $$4.05
Average Analyst Price Target: $5.56 (37.28%)
Market Cap: $$473.96M
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Justin Keywood, analyst at Stifel Nicolaus, reiterates coverage on Knight Therapeutics (KHTRF) in the Healthcare sector with a Hold rating and a price target of n/a (2 days ago).
TipRanks.com also reports that Knight Therapeutics currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $5.56 . The target pricing ranges from a high forecast of $5.76 down to a low forecast of $5.15. Knight Therapeutics (KHTRF)’s last closing price was $$4.05 which would put the average price target at 37.28% upside.Here are 3rd party ratings for KHTRF:
- TipRanks.com: Strong Buy
- TradingView.com: n/a
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: sell
- Zacks.com: n/a, n/a
--------------------------------------------------------------------------
Nkarta
Symbol: NKTX
Recent Price: $$12.43
Average Analyst Price Target: $50.00 (302.25%)
Market Cap: $$600.90M
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Dane Leone, analyst at Raymond James, reiterates coverage on Nkarta (NKTX) in the Healthcare sector with a Buy rating and a price target of $ 32 (2 weeks ago).
TipRanks.com also reports that Nkarta currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $50.00 . The target pricing ranges from a high forecast of $81.00 down to a low forecast of $32.00. Nkarta (NKTX)’s last closing price was $$12.43 which would put the average price target at 302.25% upside.Here are 3rd party ratings for NKTX:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Bottom 41% (149 out of 253)
--------------------------------------------------------------------------
Privia Health Group
Symbol: PRVA
Recent Price: $$18.74
Average Analyst Price Target: $37.70 (101.17%)
Market Cap: $$2.03B
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Adam Ron, analyst at Bank of America Securities, reiterates coverage on Privia Health Group (PRVA) in the Healthcare sector with a Buy rating and a price target of $ 27 (1 week ago).
TipRanks.com also reports that Privia Health Group currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $37.70 . The target pricing ranges from a high forecast of $45.00 down to a low forecast of $27.00. Privia Health Group (PRVA)’s last closing price was $$18.74 which would put the average price target at 101.17% upside.Here are 3rd party ratings for PRVA:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 26% (186 out of 253)
--------------------------------------------------------------------------
Ventyx Biosciences
Symbol: VTYX
Recent Price: $$13.48
Average Analyst Price Target: $41.60 (208.61%)
Market Cap: $$686.25M
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Tiago Fauth, analyst at Credit Suisse, reiterates coverage on Ventyx Biosciences (VTYX) in the Healthcare sector with a Buy rating and a price target of $ 53 (3 days ago).
TipRanks.com also reports that Ventyx Biosciences currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $41.60 . The target pricing ranges from a high forecast of $53.00 down to a low forecast of $30.00. Ventyx Biosciences (VTYX)’s last closing price was $$13.48 which would put the average price target at 208.61% upside.Here are 3rd party ratings for VTYX:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: n/a
- Zacks.com: Hold, Bottom 41% (149 out of 253)
--------------------------------------------------------------------------
Veru
Symbol: VERU
Recent Price: $$8.16
Average Analyst Price Target: $29.20 (257.84%)
Market Cap: $$653.21M
Last Year's EPS:
Consensus EPS Forecast:
Expected Earnings Date:
Recent Analyst Action: Yi Chen, analyst at H.C. Wainwright, reiterates coverage on Veru (VERU) in the Healthcare sector with a Buy rating and a price target of $ 24 (14 hours ago).
TipRanks.com also reports that Veru currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $29.20 . The target pricing ranges from a high forecast of $36.00 down to a low forecast of $24.00. Veru (VERU)’s last closing price was $$8.16 which would put the average price target at 257.84% upside.Here are 3rd party ratings for VERU:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak buy
- Zacks.com: Hold, Bottom 28% (183 out of 253)
--------------------------------------------------------------------------
To Your Financial Future,
The Editor, HealthTechMovers.com
